The American journal of psychiatry
Audio Summaries

Schizophrenia Beyond Genome-Wide Association Studies: It's About Time

Aug 1, 2026

The authors investigate how the complex interplay between genetic risk factors and environmental influences contributes to the variability in schizophrenia expression over time. They propose that shifting gene coexpression patterns throughout development may elucidate the dynamic nature of risk and suggest that studying these interactions could lead to novel treatments and preventive strategies for schizophrenia. Ultimately, they aim to understand how individual experiences shaped by genetic and environmental factors can inform better management of the disorder.

Determinants of Nonspecific Response to Treatment in Randomized Controlled Trials of Major Depressive Disorder: A Narrative Review

Jul 29, 2026

The authors review the various determinants of nonspecific response to treatment (NSRT) in randomized controlled trials for major depressive disorder (MDD), aiming to identify factors that complicate the design and interpretation of these studies. They discuss the influence of the placebo effect, misdiagnosis, and other variables on trial outcomes, and propose strategies to mitigate these issues, such as standardized training and independent diagnostic confirmation. The review emphasizes the need for uniform definitions and approaches among experts to enhance the development of effective treatments for MDD.

Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial

Jul 29, 2026

This study aimed to evaluate the effects of oral semaglutide on alcohol craving and consumption in treatment-seeking adults with alcohol use disorder (AUD). While semaglutide did not significantly reduce laboratory-assessed craving, it was associated with a notable decrease in heavy drinking days, drinks per drinking day, and alcohol-related consequences compared to placebo. The results support further investigation into semaglutide as a potential treatment for AUD.

Global Prevalence of Obsessive-Compulsive and Related Disorders: A Systematic Review and Modeling Study

Jul 8, 2026

The authors aimed to address the gap in epidemiological data regarding the global prevalence of obsessive-compulsive disorder (OCD) and related disorders. Through a systematic review and modeling study, they estimated the lifetime prevalence of OCD to be approximately 2.57% to 3.21% depending on the diagnostic criteria used, and found a negative correlation between OCD prevalence and the Socio-demographic Index, with prevalence peaking in young adulthood. The study highlights the importance of diagnostic definitions in understanding the epidemiology of these mental health disorders.

Treatment Patterns and Barriers to Care Among U.S. Adults With Co-Occurring Substance Use Disorder and Mental Illness

Jul 8, 2026

This study investigates treatment patterns and barriers to care for U.S. adults with co-occurring substance use disorder (SUD) and mental illness, utilizing data from the National Survey on Drug Use and Health. The authors found that while there was a modest increase in treatment rates from 2021 to 2023, significant disparities and barriers—such as stigma, cost, and limited access—persisted, highlighting the need for improved coordination and enforcement of parity in behavioral health services.

Convergent Network Localization of Brain Stimulation Targets for Trait Anxiety

Jul 8, 2026

The authors aimed to identify specific brain circuits that can be targeted for stimulation to modify anxiety, utilizing data from patients with brain lesions, TMS, and DBS. Their findings revealed a convergent anxiety circuit, particularly highlighting the right superior frontal gyrus as a potential therapeutic target, and demonstrated that individual connectivity to this circuit correlates with treatment outcomes. This research underscores a novel approach for pinpointing stimulation targets across various neuropsychiatric conditions.

Social Determinants of Health in Psychiatric Disorders: Exciting Opportunities for Biopsychosocial Research and Clinical Care

Jul 1, 2026

The authors explore how social determinants of health (SDoHs) impact psychiatric disorders and emphasize the need for their integration into clinical practice and research. They propose a biopsychosocial framework that connects social exposures, biological mechanisms, and psychological processes to better understand mental health risks and interventions. The paper highlights the importance of assessing SDoHs and suggests leveraging digital technologies to enhance mental health care globally.

Deadly Heat: The Association Between Ambient Temperature and Suicide in Young People in the United States

Jun 24, 2026

The authors investigate the relationship between ambient temperature and suicide rates among young people (ages 5-24) in the United States, particularly focusing on seasonal variations. Their findings reveal that suicide rates increase significantly with rising temperatures, especially during summer months, with the most pronounced effect observed in individuals aged 15-24. This study underscores the need for further research on the mental health impacts of heat on youth and the development of targeted interventions.

Circadian Rhythm Stabilization App to Prevent Mood Episode Recurrence in Patients With Mood Disorders: A Multicenter, Double-Blind, Sham-Controlled, Randomized Clinical Trial

Jun 24, 2026

The authors aimed to evaluate the efficacy of the Circadian Rhythm for Mood (CRM) smartphone app in preventing mood episode recurrence in patients with major depressive disorder (MDD) and bipolar disorder (BD). In a randomized clinical trial involving 93 adults, the CRM app significantly reduced the recurrence rate of mood episodes compared to a sham app, suggesting its potential as a digital adjunct to standard care for mood disorders.

A Pragmatic SMART Study of Medication and CBT Sequencing in Pediatric Anxiety Disorders: A Randomized Clinical Trial

Jun 24, 2026

The authors aimed to determine whether starting treatment for pediatric anxiety disorders with fluoxetine or cognitive-behavioral therapy (CBT) leads to better outcomes, and how to optimize treatment if initial care is insufficient. The study found that symptom reduction was similar across all treatment sequences, with no significant advantage of combination therapy over monotherapy after three months. Additionally, the effectiveness of treatment varied by racial and ethnic background, suggesting the importance of tailoring approaches to individual patient preferences.